Cost-effectiveness of first-v.second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy

<jats:sec><jats:title>Background</jats:title><jats:p>There are claims that the extra costs of atypical (second-generation) antipsychotic drugs over conventional (first-generation) drugs are offset by improved health-related quality of life.</jats:p></jats:sec><jats:sec><jats:title>Aims</jats:title><jats:p>To determine the relative costs and value of treatment with conventional or atypical antipsychotics in people with schizophrenia.</jats:p></jats:sec><jats:sec><jats:title>Method</jats:title><jats:p>Cost-effectiveness acceptability analysis integrated clinical and economic randomised controlled trial data of conventional and atypical antipsychotics in routine practice.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Conventional antipsychotics had lower costs and higher quality-adjusted life-years (QALYs) than atypical antipsychotics and were more than 50% likely to be cost-effective.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The primary and sensitivity analyses indicated that conventional antipsychotics may be cost-saving and associated with a gain in QALYs compared with atypical antipsychotics.</jats:p></jats:sec>